SYRE
Spyre Therapeutics, Inc. NASDAQ$69.13
Mkt Cap $4.2B
52w Low $12.29
89.2% of range
52w High $76.00
50d MA $52.18
200d MA $31.23
P/E (TTM)
-35.1x
EV/EBITDA
-53.7x
P/B
33.6x
Debt/Equity
0.0x
ROE
-21.7%
P/FCF
-67.0x
RSI (14)
—
ATR (14)
—
Beta
2.94
50d MA
$52.18
200d MA
$31.23
Avg Volume
977.0K
About
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002,…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 19, 2026 | BMO | -0.66 | -0.70 | -6.1% | 37.81 | +0.0% | +14.3% | +14.3% | +16.8% | +14.9% | +16.1% | — |
| Nov 4, 2025 | BMO | -0.68 | -0.15 | +77.9% | 22.98 | +1.7% | -0.6% | -0.6% | -2.6% | -2.0% | -3.5% | — |
| Aug 5, 2025 | BMO | -0.73 | -0.49 | +32.9% | 16.87 | +0.1% | -5.4% | -5.4% | -9.7% | -10.1% | -9.6% | — |
| May 8, 2025 | BMO | -0.76 | -0.74 | +2.6% | 12.86 | +5.3% | +9.6% | +9.6% | +16.1% | +14.7% | +15.1% | — |
| Feb 27, 2025 | BMO | -0.89 | -0.81 | +9.0% | 18.37 | +1.7% | +7.2% | +7.2% | -2.3% | -0.8% | +6.0% | — |
| Nov 7, 2024 | BMO | -0.80 | -1.36 | -70.0% | 37.69 | -4.8% | +5.0% | +5.0% | +4.4% | -5.0% | -12.5% | — |
| Aug 7, 2024 | BMO | -0.90 | -0.86 | +4.4% | 24.55 | +3.6% | +2.9% | +2.9% | +1.0% | -1.0% | +3.0% | — |
| May 9, 2024 | BMO | -0.90 | -1.20 | -33.3% | 35.19 | +9.8% | +4.9% | +4.9% | +5.1% | +11.7% | +6.2% | — |
| Feb 29, 2024 | BMO | -0.48 | -2.28 | -375.0% | 27.44 | +10.0% | +9.0% | +9.0% | +27.4% | +37.2% | +46.7% | — |
| Nov 9, 2023 | BMO | -0.84 | -9.34 | -1011.9% | 9.47 | -2.5% | +0.2% | +0.2% | +7.5% | +13.5% | +14.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 17 | Jones Trading | Maintains | Buy → Buy | — | $69.70 | $70.32 | +0.9% | +4.7% | +5.3% | +2.3% | +4.7% | -0.7% |
| Apr 14 | Baird | Maintains | Outperform → Outperform | — | $63.27 | $67.68 | +7.0% | +1.2% | +9.0% | +10.2% | +15.4% | +16.0% |
| Apr 14 | Wells Fargo | Maintains | Overweight → Overweight | — | $63.27 | $67.68 | +7.0% | +1.2% | +9.0% | +10.2% | +15.4% | +16.0% |
| Apr 14 | Wedbush | Maintains | Outperform → Outperform | — | $63.27 | $67.68 | +7.0% | +1.2% | +9.0% | +10.2% | +15.4% | +16.0% |
| Apr 14 | Deutsche Bank | Maintains | Buy → Buy | — | $63.27 | $67.68 | +7.0% | +1.2% | +9.0% | +10.2% | +15.4% | +16.0% |
| Apr 13 | BTIG | Maintains | Buy → Buy | — | $51.29 | $67.00 | +30.6% | +23.4% | +24.8% | +34.5% | +35.9% | +42.3% |
| Apr 13 | Leerink Partners | Maintains | Outperform → Outperform | — | $51.29 | $67.00 | +30.6% | +23.4% | +24.8% | +34.5% | +35.9% | +42.3% |
| Apr 13 | Jefferies | Maintains | Buy → Buy | — | $51.29 | $67.00 | +30.6% | +23.4% | +24.8% | +34.5% | +35.9% | +42.3% |
| Mar 31 | BTIG | Maintains | Buy → Buy | — | $45.42 | $46.28 | +1.9% | +11.1% | +7.7% | +4.8% | +7.8% | +12.7% |
| Mar 18 | Stifel | Maintains | Buy → Buy | — | $43.95 | $44.28 | +0.8% | -2.0% | -3.7% | -6.1% | -2.7% | -3.9% |
Recent Filings
8-K · 2.02
!! High
Spyre Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Spyre Therapeutics disclosed financial results and operational performance through a press release, providing investors with updated insight into the company's earnings and current business conditions.
May 5
8-K
Unknown — 8-K Filing
Syros Pharmaceuticals completed a securities offering in April 2026, likely diluting existing shareholders but providing capital for operations or acquisitions that investors should monitor for strategic impact.
Apr 16
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Syros' SKYLINE trial advancement delays proof-of-concept data to mid-2026 and Q3 2026, pushing potential catalysts back and increasing execution risk for investors awaiting clinical validation.
Apr 13
8-K
Unknown — 8-K Filing
Syros Pharmaceuticals suspended its ATM offering effective April 13, 2026, eliminating a key funding mechanism and signaling potential cash constraints or reduced near-term capital needs for the biotech company.
Apr 13
8-K
Spyre Therapeutics, Inc. -- 8-K Filing
Spyre Therapeutics announced full-year 2025 financial results and expects Phase 2 trial data that could validate its long-acting antibody platform for treating inflammatory bowel disease and rheumatic diseases, potentially driving clinical advancement.
Feb 19
Data updated apr 27, 2026 3:52am
· Source: massive.com